BRCA2 and ovarian carcinoma: This “LOH reversal” was observed in two BRCA2 mutation carriers with breast cancer, treated with non-platinum chemotherapy and radiation, and two BRCA1 mutation carriers with ovarian cancer, both treated with platinums.